… effectiveness and optimum use of tocilizumab (TCZ) treatment … total duration of hospitalization
after administration of TCZ was … Comparison of the patients who were given tocilizumab …

… ] and may provide clinical benefit for selected COVID–19 patients with high inflammatory
biomarkers. We hereby report our experience with using tocilizumab in hospitalized patients …

… Additionally, there is concern that exposure to tocilizumab may lead to increased risk of …
We hypothesized that patients with severe COVID-19 who received tocilizumab would have …

… and need for mechanical ventilation, in hospitalized patients with COVID-19 infection …
tocilizumab therapy in hospitalized COVID-19 patients and strengthen the concept that tocilizumab …

… of patients with COVID-19 receiving tocilizumab for the treatment of inflammatory-related
lung injury. Time from lung injury onset to tocilizumab administration may be critical to patient …

… , which suggests that later administration of TCZ in critically ill patients with evidence of an …
Remarkably, of the 12 patients who died during the TCZ treatment, 58.3% patients had higher …

… Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. …

… We started using tocilizumab in patients with respiratory failure, and … administration of
methylprednisolone treatment, followed in more severe cases by the administration of tocilizumab. …

… of administration, drug–drug interactions, and metabolism, we aimed to investigate whether
baricitinib was non-inferior to tocilizumab in hospitalized patients with severe COVID-19. …

… patients enrolled in the tocilizumab group and 6160 patients in the SOC group, were included
in this meta-analysis. Compared to the SOC, tocilizumab … no difference in hospital length of …